



Therapy	Target/Modality	Indications	Preclinical	Phase 1	Phase 2	Phase 2 Reg / Phase 3	FDA status
Magrolimab + Azacitidine	CD47 antibody	MDS				FortySeven <sup>1</sup>	
AFM13	CD30/CD16A bispecific engager	PTCL				affimed	
Pelabresib + Ruxolitinib	BET small molecule	MPN				Constellation PHARMACEUTICALS	
Duvelisib	PI3Kδ/γ small molecule	PTCL				Verastem <sup>2</sup> Oncology	
Magrolimab + Rituximab	CD47 antibody	DLBCL				FortySeven <sup>1</sup>	
Cusatuzumab + Azacitidine	CD70 antibody	AML				argenx <sup>3</sup>	
K-NK002	NK cell therapy	AML/MDS				Kiadis <sup>4</sup>	
KO-539	Menin small molecule	MLL leukemia		KURA <sup>5</sup> ONCOLOGY			
STRO-001	CD74 antibody drug conjugate	MM/DLBCL/ MCL/FL		SUTRO BIOPHARMA			(MM)
Mavorixafor + Ibrutinib	CXCR4 small molecule	Waldenström macroglobulinemia		X4 PHARMACEUTICALS			
SEL120	CDK8/19 small molecule	AML/MDS		RYVU THERAPEUTICS			
PVX-410 + ACY-241 +/- Len	XBP1/CD138/CS1 vaccine	Smoldering myeloma		OncoPep			
NEXI-001 NEXI-002	T cell therapy	AML MM		NexImmune			
BTX-A51	CK1-α/CDK7/CDK9 small molecule	AML/MDS		BioTherapyX			
IO-202	LILRB4 antibody	AML/CMML		IMMUNE-ONC THERAPEUTICS			
CB-010	CD19/PD1 KO allogeneic CAR	NHL		CARIBOU BIOSCIENCES			
KT-413	IRAK4IMiD heterobifunctional degrader	Lymphoma	KYMERA				
TBD	<i>in vivo</i> CAR	Hematological malignancies	ABINTUS				
TBD	CAR macrophage	Hematological malignancies	carisma THERAPEUTICS				

Orphan Drug Designation

Fast Track Designation

Breakthrough Therapy Designation

1: Acquired by Gilead ♦ 2: Duvelisib acquired by Secura Bio ♦ 3: Collaboration with Janssen ♦ 4: Acquisition by Sanofi announced ♦ 5: Licensed from University of Michigan